Liquid Biopsy and ddPCR: A Match with Quality in Mind

Tuesday, January 29th, 2019

8:00 am PT, 11:00 am ET, 17:00 CET


Liquid biopsies represent one of the most innovative and cutting-edge scientific techniques to break into the clinical arena in the past decade. The testing of plasma samples for the presence of mutations in circulating tumor DNA (ctDNA) to aid in the diagnosis and treatment of cancer is an exciting new development in providing non-invasive options for patients. While liquid biopsies possess massive diagnostic potential, the method is only as good as the quality of the DNA samples being tested, and there are many challenges with the introduction of this new type of sample—in particular, the need for highly sensitive and precise testing methods. Droplet digital PCR (ddPCR) meets both testing needs for sensitivity and precision and has emerged as a go-to method for assessing the quality of patient-derived DNA samples from plasma. Additionally, the application of such highly sensitive testing platforms requires validating the quality of the processes and one mechanism to measure the standard of testing is through external quality assessment (EQA). In this Clinical OMICs webinar, we will hear how GenQA (Genomics Quality Assessment), a non-profit EQA provider that promotes high quality accurate genetic testing and educational services, addresses some of the challenges in providing quality assessments for ctDNA testing.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelist.

Jenni Fairley, PhD
Deputy Scheme Director (Molecular Pathology)
Dawne Shelton, PhD
R & D Manager
Bio-Rad Laboratories

Registration details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)